v3.26.1
Condensed Consolidated Statements of Change in Stockholders’ Deficit (Unaudited) - USD ($)
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total
Balance at Jun. 30, 2024 $ 330 $ 7,024,162 $ (11,026,928) $ (4,002,436)
Balance (in Shares) at Jun. 30, 2024 [1] 3,303,333        
Conversion of convertible promissory notes into common stock upon completion of reverse recapitalization $ 170 15,408,515 15,408,685
Conversion of convertible promissory notes into common stock upon completion of reverse recapitalization (in Shares) [1] 1,696,668        
Issuance of common stock upon completion of reverse recapitalization $ 227 (2,100,865) (2,100,638)
Issuance of common stock upon completion of reverse recapitalization (in Shares) [1] 2,270,096        
Earnout liabilities (5,688,007) (5,688,007)
Transaction costs (893,577) (893,577)
Net income/(loss) (2,266,789) (2,266,789)
Balance at Sep. 30, 2024 $ 727 13,750,228 (13,293,717) 457,238
Balance (in Shares) at Sep. 30, 2024 [1] 7,270,097        
Balance at Jun. 30, 2024 $ 330 7,024,162 (11,026,928) (4,002,436)
Balance (in Shares) at Jun. 30, 2024 [1] 3,303,333        
Foreign currency translation         (412)
Net income/(loss)         (4,927,154)
Balance at Mar. 31, 2025 $ 678 14,398,569 (15,954,082) (412) (1,555,247)
Balance (in Shares) at Mar. 31, 2025 [1] 6,780,597        
Balance at Sep. 30, 2024 $ 727 13,750,228 (13,293,717) 457,238
Balance (in Shares) at Sep. 30, 2024 [1] 7,270,097        
Issuance of common stock through exercise of warrants $ 1 120,749   120,750
Issuance of common stock through exercise of warrants (in Shares) [1] 10,500        
Stock-based compensation expenses 200,954   200,954
Net income/(loss) 1,424,146   1,424,146
Balance at Dec. 31, 2024 $ 728 14,071,931 (11,869,571) 2,203,088
Balance (in Shares) at Dec. 31, 2024 [1] 7,280,597        
Stock-based compensation expenses 326,588 326,588
Foreign currency translation (412) (412)
Cancellation of common stock held in escrow $ (50) 50
Cancellation of common stock held in escrow (in Shares) [1] (500,000)        
Net income/(loss) (4,084,511) (4,084,511)
Balance at Mar. 31, 2025 $ 678 14,398,569 (15,954,082) (412) (1,555,247)
Balance (in Shares) at Mar. 31, 2025 [1] 6,780,597        
Balance at Jun. 30, 2025 $ 678 14,686,705 (20,047,064) (5,002) $ (5,364,683)
Balance (in Shares) at Jun. 30, 2025 6,780,597       6,780,597
Stock-based compensation expenses 296,797 $ 296,797
Foreign currency translation (6,525) (6,525)
Net income/(loss) (2,865,442) (2,865,442)
Balance at Sep. 30, 2025 $ 678 14,983,502 (22,912,506) (11,527) (7,939,853)
Balance (in Shares) at Sep. 30, 2025 6,780,597        
Balance at Jun. 30, 2025 $ 678 14,686,705 (20,047,064) (5,002) $ (5,364,683)
Balance (in Shares) at Jun. 30, 2025 6,780,597       6,780,597
Foreign currency translation         $ (12,109)
Net income/(loss)         (43,421,349)
Balance at Mar. 31, 2026 $ 700 15,669,020 (63,468,413) (17,111) $ (47,815,804)
Balance (in Shares) at Mar. 31, 2026 7,005,191       7,005,191
Balance at Sep. 30, 2025 $ 678 14,983,502 (22,912,506) (11,527) $ (7,939,853)
Balance (in Shares) at Sep. 30, 2025 6,780,597        
Issuance of common stock under EIP $ 18 (18)
Issuance of common stock under EIP (in Shares) 182,214        
Stock-based compensation expenses 406,322 406,322
Foreign currency translation (2,266) (2,266)
Net income/(loss) (4,285,914) (4,285,914)
Balance at Dec. 31, 2025 $ 696 15,389,806 (27,198,420) (13,793) (11,821,711)
Balance (in Shares) at Dec. 31, 2025 6,962,811        
Issuance of common stock under EIP $ 4 (4)
Issuance of common stock under EIP (in Shares) 42,380        
Stock-based compensation expenses 279,218 279,218
Foreign currency translation (3,318) (3,318)
Net income/(loss) (36,269,993) (36,269,993)
Balance at Mar. 31, 2026 $ 700 $ 15,669,020 $ (63,468,413) $ (17,111) $ (47,815,804)
Balance (in Shares) at Mar. 31, 2026 7,005,191       7,005,191
[1] Giving retroactive effect to reverse recapitalization effected on September 26, 2024 to reflect exchange ratio of approximately 3.3033 as described in Note 4.